VRDN — Viridian Therapeutics, Inc.\DE

Nasdaq · Health Care · Pharmaceuticals · CIK 1590750 ·
Last close
$17.00
Market Cap
$1.88B
52W High
$30.79
52W Low
$13.18
ADV30
2,950,005
Next earnings
2026-08-06
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 141,000 -116,169,000 -104,901,000 789,017,000 176,346,000 153,009,000
Dec 2025 132,000 -122,749,000 -120,355,000 899,418,000 212,382,000 177,251,000
Sep 2025 70,570,000 -40,013,000 -34,599,000 577,138,000 169,647,000 74,168,000
Jun 2025 75,000 -106,767,000 -100,735,000 582,324,000 117,324,000 67,155,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-276,391,000
Investing CF
$-37,563,000
Financing CF
$426,742,000
CapEx
$-495,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-3.29
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,338,458,000
Inventory
Receivables
$70,000,000
ST Investments
$662,270,000
EBIT TTM
$-337,659,000
Pretax Income TTM
$-342,601,000
Interest Exp TTM
$4,942,000
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$70,918,000
EBITDA
$-385,233,984
Free Cash Flow
$-182,550,752
Enterprise Value
$1,200,233,472
Total Cash
$762,180,992
Total Debt
$53,350,000
Shares Out
110,427,682
Trailing EPS
$-3.35
Book Value
$5.79
ROE
-58.1%
ROA
-33.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 70,849,000 -363,395,000 -342,601,000 899,418,000 177,251,000 -276,391,000
Dec 2024 302,000 -299,035,000 -269,949,000 742,403,000 70,764,000 -232,319,000
Dec 2023 314,000 -254,450,000 -237,734,000 490,424,000 48,402,000 -184,170,000
Dec 2022 1,772,000 -134,304,000 -129,874,000 435,091,000 40,027,000 -93,838,000

TTM Snapshot

Revenues TTM
$1,561,000
NetIncome TTM
$-167,297,000
OpCashFlow TTM
$0
Assets (Latest)
$742,403,000
Forward EPS
$-2.51

Max Pain — expiry 2026-07-17

max pain strike: $15.00 · spot: $17.00 · call oi: 4,891 · put oi: 237
Expected Move to 2026-07-17: ±$5.58 (32.79%) — implied range $11.43$22.57 · ATM straddle on $17.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AAPG ASCENTAGE PHARMA GROUP INTERNATIONAL $1.88B $20.13
HMDCF HUTCHMED (China) Ltd $1.86B $2.16
RAPP Rapport Therapeutics, Inc. $1.90B $39.71
ZYME Zymeworks Inc. $1.85B $25.40
ANIP ANI PHARMACEUTICALS INC $1.85B $81.41

News headlines (Yahoo Finance, 1h cache)

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M
2026-05-21 13:30 · Yahoo
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million
2026-05-17 18:52 · Yahoo
Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising
2026-05-08 08:18 · Yahoo
Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates
2026-05-07 19:41 · Yahoo
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
2026-05-07 03:13 · Yahoo
Viridian Therapeutics’ stock up 35% after Phase III TED data release
2026-05-06 12:13 · Yahoo
Viridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TED
2026-05-06 08:24 · Yahoo
Viridian (VRDN) Climbs 33% on Looming Drug Commercialization
2026-05-06 01:50 · Yahoo
How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye Disease
2026-05-05 20:24 · Yahoo
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
2026-05-05 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.